Doravirine/islatravir (Idvynso) vs Ulonivirine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Doravirine/islatravir (Idvynso)

Marketed by Merck & Co.

Approved in HIVsmall molecule
Partial signal

NCT05631093 · Phase 3 · active, not recruiting

Trial 051 randomized 551 virologically suppressed adults with HIV-1 2:1, open-label, to switch to once-daily doravirine/islatravir or stay on their baseline antiretroviral regimen. The primary efficacy endpoint was the proportion with HIV-1 RNA at or above 50 copies/mL at Week 48, tested for non-inferiority with a 4-percentage-point margin. The rate was 1.4% after the switch and 4.9% on baseline therapy (difference -3.58, 95% CI -7.81 to -0.77), so non-inferiority was shown and the primary endpoint was met. The other registered primaries are adverse-event rates. Source: ClinicalTrials.gov posted results and the IDVYNSO US label, section 14.

Next expected readout: May 2029 · NCT04776252 (registry estimate)

Reported efficacy

Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48; Percentage of Participants Who Experience Adverse Events (AEs) Through Week 48; Percentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 48: HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results). (met)

Result source: NCT05630755

Ulonivirine

Developed by Merck & Co.

Phase 2/3 in HIVsmall molecule
Weak signal

NCT04564547 · Phase 2 · completed

Randomized, triple-masked phase 2b switch study of once-weekly islatravir plus ulonivirine in virologically suppressed HIV-1 infection (161 participants). All three primary endpoints are adverse-event rates reported descriptively; no efficacy comparison was posted as primary. Its registered primary outcome on ClinicalTrials.gov is "Percentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind" (with 2 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: August 2027 · NCT06891066 (registry estimate)

Reported efficacy

Percentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind (Up to approximately 9 months); Percentage of Participants Who Discontinued Study Intervention Due to an AE During the Double-Blind Treatment Period (Up to approximately 8 months); Percentage of Participants Who Experienced One or More AEs During the Unblinded Safety Monitoring Period (Up to approximately 37 months): Percentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind (Up to approximately 9 months): Group 1: ISL 20 mg + Ulonivirine 100 mg 75 Percentage of Participants | Group 2: ISL 20 mg + Ulonivirine 200 mg 75.6 Percentage of Participants | Group 3: ISL 20 mg + Ulonivirine 400 mg 80 Percentage of Participants | Group 4: BIC/FTC/TAF 67.5 Percentage of Participants (not_applicable)

Result source: NCT04564547

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDoravirine/​islatravir (Idvynso)Ulonivirine
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT05630755—Trial running · NCT07266831
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT05630755—Trial running · NCT07266831
CD4 count, change (week 48)—Trial running · NCT05630755—Trial running · NCT07266831

HIV-1 RNA below 50 copies/mL (week 48)

Doravirine/​islatravir (Idvynso)
—Trial running · NCT05630755
Ulonivirine
—Trial running · NCT07266831

HIV-1 RNA 50 copies/mL or more (week 48)

Doravirine/​islatravir (Idvynso)
—Trial running · NCT05630755
Ulonivirine
—Trial running · NCT07266831

CD4 count, change (week 48)

Doravirine/​islatravir (Idvynso)
—Trial running · NCT05630755
Ulonivirine
—Trial running · NCT07266831
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Doravirine/islatravir (Idvynso)
Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 (Week 48): Group 1: DOR/ISL 88.9% vs Group 2: BIC/FTC/TAF 88.3% NCT04233879 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=366) vs staying on baseline ART (n=185): 1.4% vs 4.9%; difference -3.58 percentage points (95% CI -7.81 to -0.77), non-inferiority p < 0.001 against a 4-point margin (CT.gov posted results). NCT05631093 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results). NCT05630755 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48 (Week 48): Group 1: Doravirine/Islatravir (DOR/ISL) 0% vs Group 2: Baseline Antiretroviral Therapy (ART) 1.5% NCT04223778 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Week 48 HIV-1 RNA ≥50 copies/mL: 0.6% DOR/ISL vs 0.3% BIC/FTC/TAF; treatment difference 0.31 percentage points (95% CI -1.19 to 1.96; p<.001); prespecified non-inferiority margin was 4 percentage points. NCT04223791 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Doravirine/islatravir (Idvynso): 0 of 4 rows · Ulonivirine: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricUlonivirine
Dropout rate
5%400 mg weeklya
NCT04564547 · Phase 2 · combination
show 8 more results
—400 mg weekly
NCT04564547 · Phase 2 · combination
—400 mg weekly
NCT04564547 · Phase 2 · combination
4.9%200 mg weekly
NCT04564547 · Phase 2 · combination
—200 mg weekly
NCT04564547 · Phase 2 · combination
—200 mg weekly
NCT04564547 · Phase 2 · combination
7.5%100 mg weekly
NCT04564547 · Phase 2 · combination
—100 mg weekly
NCT04564547 · Phase 2 · combination
—100 mg weekly
NCT04564547 · Phase 2 · combination
Discontinued due to AEs
—400 mg weeklya
NCT04564547 · Phase 2 · combination
show 8 more results
—400 mg weekly
NCT04564547 · Phase 2 · combination
—400 mg weekly
NCT04564547 · Phase 2 · combination
—200 mg weekly
NCT04564547 · Phase 2 · combination
—200 mg weekly
NCT04564547 · Phase 2 · combination
—200 mg weekly
NCT04564547 · Phase 2 · combination
—100 mg weekly
NCT04564547 · Phase 2 · combination
—100 mg weekly
NCT04564547 · Phase 2 · combination
—100 mg weekly
NCT04564547 · Phase 2 · combination
Serious AEs
—400 mg weeklya
NCT04564547 · Phase 2 · combination
show 8 more results
2.5%400 mg weekly
NCT04564547 · Phase 2 · combination
2.7%400 mg weekly
NCT04564547 · Phase 2 · combination
—200 mg weekly
NCT04564547 · Phase 2 · combination
7.3%200 mg weekly
NCT04564547 · Phase 2 · combination
0%200 mg weekly
NCT04564547 · Phase 2 · combination
—100 mg weekly
NCT04564547 · Phase 2 · combination
5%100 mg weekly
NCT04564547 · Phase 2 · combination
0%100 mg weekly
NCT04564547 · Phase 2 · combination
Most frequent reported AEs
400 mg weeklya
covid-19 17.5%
diarrhoea 15%
fatigue 12.5%
NCT04564547 · Phase 2 · combination
show 5 more results
400 mg weekly
covid-19 29.7%
arthralgia 5.4%
fatigue 5.4%
NCT04564547 · Phase 2 · combination
200 mg weekly
covid-19 9.8%
asthenia 7.3%
diarrhoea 7.3%
NCT04564547 · Phase 2 · combination
200 mg weekly
covid-19 17.9%
back pain 5.1%
bronchitis 5.1%
NCT04564547 · Phase 2 · combination
100 mg weekly
headache 12.5%
fatigue 10%
covid-19 7.5%
NCT04564547 · Phase 2 · combination
100 mg weekly
covid-19 10.8%
diarrhoea 5.4%
sinusitis 5.4%
NCT04564547 · Phase 2 · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Doravirine/islatravir (Idvynso)'s landscape · Ulonivirine's landscape